Compare Anheuser-Busch Inbev SA (BUD) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Smith & Nephew plc — how do they compare? Anheuser-Busch Inbev SA trades at $79.68 (market cap $159.01B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Anheuser-Busch Inbev SA is far larger — about 12.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| BUD | SNN | |
|---|---|---|
Market Cap | $159.01B | $12.54B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $38.70 |
52-Week Low | $57.93 | $28.73 |
Enterprise Value | $223.42B | $15.57B |
Dividend Yield | 1.67% | 2.65% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
